全球血友病市场 – 行业趋势和 2031 年预测

血友病市场分析和规模

血友病基因治疗涉及使用基因工程技术将缺陷凝血因子基因（血友病 A 的因子 VIII 或血友病 B 的因子 IX）的功能性拷贝引入患者细胞。这种方法旨在使体内产生凝血因子，可能为血友病治疗提供长期甚至永久的解决方案。最近的进展已显示出令人鼓舞的结果，正在进行的临床试验证明了基因治疗在减少出血事件和减少对常规凝血因子替代疗法的依赖方面的可行性和有效性。

2023 年全球血友病市场规模价值 121.6 亿美元，预计到 2031 年将达到 218.4 亿美元，2024 年至 2031 年预测期内的复合年增长率为 7.6%。

除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Haemophilia is a genetic disorder characterized by impaired blood clotting due to deficient or absent clotting factors in the blood. This condition leads to prolonged bleeding episodes, both internally and externally, which can be spontaneous or caused by injury. Management typically involves replacement therapy to restore clotting factor levels and prevent complications from bleeding episodes.

Haemophilia Market Dynamics

Drivers

• Growing Incidence of Haemophilia

Increasing incidence of haemophilia is attributed to several factors, including improved diagnosis capabilities, broader access to healthcare services, and heightened awareness among healthcare professionals and the general population. Additionally, genetic predisposition and demographic changes such as population growth and aging contribute to a larger patient pool requiring treatment. This trend fuels demand for clotting factor replacement therapies and encourages research into innovative treatments such as gene therapy. As the prevalence continues to grow globally, pharmaceutical companies and healthcare providers are motivated to develop and enhance therapies, thus driving market expansion and evolution.

• Increasing Disease Awareness

Enhanced awareness campaigns and educational initiatives contribute to earlier diagnosis and prompt initiation of treatment, which is critical for managing haemophilia effectively. As awareness grows, more patients are likely to seek medical care and adhere to treatment regimens, thereby expanding the market for clotting factor replacement therapies and emerging treatments such as gene therapy.                                                                              

Opportunities

• Increasing Technological Advancements

Biotechnological breakthroughs have led to the development of more effective clotting factor replacement therapies, such as extended half-life products that reduce treatment frequency and improve convenience for patients. Moreover, advancements in gene therapy and gene editing technologies offer promising avenues towards potential cures by correcting the genetic defects underlying haemophilia. Improved diagnostic tools and monitoring devices enhance precision in treatment delivery and patient management, contributing to better outcomes and quality of life. These technological strides continue to shape the landscape of haemophilia treatment, fostering continuous innovation and addressing unmet medical needs in the market.

• Rising Government Initiatives

Government initiatives fosters a supportive regulatory environment, funding research and development, and improving access to treatment. Governments often collaborate with healthcare organizations and industry stakeholders to enhance awareness about haemophilia, promote early diagnosis through screening programs, and ensure affordability of therapies through healthcare reimbursement policies. By investing in infrastructure and healthcare systems, governments facilitate the availability of advanced treatments such as clotting factor replacements and gene therapies, thereby improving patient outcomes and quality of life.

Restraints/Challenges

• Stringent Regulatory Requirements

Regulatory agencies mandate rigorous clinical trials and extensive safety assessments for approval, which can delay the introduction of innovative treatments. These requirements not only increase development costs but also limit the number of therapies that successfully navigate the approval process. Additionally, differing regulatory standards across countries and regions create complexities in global market entry, further impeding timely access to new treatments for haemophilia patients worldwide.

• High Treatment Costs

The recurring expenses associated with clotting factor replacement therapies and emerging treatments such as gene therapy can impose a substantial financial burden, particularly in regions without adequate insurance coverage or healthcare subsidies. This cost barrier limits access to optimal care and innovative therapies, potentially compromising treatment outcomes and quality of life for patients. Moreover, the financial strain on healthcare budgets may delay investment in infrastructure and research, hindering advancements in haemophilia treatment options and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Haemophilia Market Scope

The market is segmented on the basis of type, treatment, route of administration, diagnosis, patient, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Type

• Haemophilia A
• Haemophilia B
• Haemophilia C
• Others

Treatment

• Medication
• Desmopressin
• Emicizumab
• Anti-fibrinolytics
• Therapy
• Factor Replacement Therapy
  • Plasma-derived Factor Concentrates
    • Factor VIII
    • Factor IX
  • Recombinant Factor Concentrates
    • Factor VIII
    • Factor VII
    • Factor IX
• Desmopressin and Fibrin Sealants
• Monoclonal Antibodies
• ITI Therapy
• Gene Therapy
• Fibrin Sealants
• Others

Route of Administration

• Oral
• Injectable
• Others

Diagnosis

• Blood Test
• Genetic Tests
• Others

Patient

• Pediatric
  • 0 to 4
  • 5 to 13
  • 14 to18
• Adult
  • 19 to 44
  • 45+

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Haemophilia Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, patient, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.

North America dominates the market due to increasing demand for specialized treatments and higher healthcare spending, which will bolster market growth. Moreover, the region's high prevalence of bleeding disorders and increasing adoption of advanced technologies are additional factors contributing to the growth trajectory of the market in North America. These dynamics position the region as a key player in the global haemophilia treatment landscape.

预计欧洲将经历快速增长，主要原因是血友病发病率不断上升。该地区强大的医疗基础设施和积极的政府举措是加速市场扩​​张的关键。这些因素预计将提高先进治疗和疗法的可及性，从而促进整个欧洲血友病护理的重大进步。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和血友病市场分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 默克公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 百特（美国）
• 武田药品工业株式会社 (日本)
• Grifols, SA（西班牙）
• 中超联赛（美国）
• BioMarin (美国)
• Spark Therapeutics, Inc.（美国）
• 中外制药株式会社（日本）
• Octapharma AG（瑞士）
• 诺和诺德公司（丹麦）
• Biogen（美国）
• 基因泰克公司（美国）
• 拜耳公司（德国）
• Ferring BV（瑞士）

SKU-53304